机译:吡咯酮衍生物作为趋化因子受体的细胞内变形调节剂:CC趋化因子受体1和2的选择性和双靶向抑制剂
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
Leiden Univ Div Drug Discovery &
Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;
机译:吡咯酮衍生物作为趋化因子受体的细胞内变形调节剂:CC趋化因子受体1和2的选择性和双靶向抑制剂
机译:CC趋化因子G蛋白偶联受体CCR4和CCR5的特定类拮抗剂的细胞内变构位点。
机译:选择性删除CC趋化因子受体5或2的小鼠受到葡聚糖硫酸钠介导的结肠炎的保护:CC趋化因子受体5的缺乏表达会导致inte NK1.1 +淋巴细胞相关的Th2型免疫应答
机译:CC趋化因子及其受体在肥大细胞生物学多个方面的作用:使用蛋白质芯片技术的Fcepsilonri-and-/或CCR1接合肥大细胞的比较蛋白质分析
机译:趋化因子CCL27的结构和功能分析以及沉默趋化因子受体D6和DARC的表达和纯化。
机译:吡咯烷酮衍生物作为细胞内变构的趋化因子受体的调节剂:选择性和双重靶向抑制剂CC趋化因子受体1和2
机译:吡咯酮衍生物作为趋化因子受体的细胞内变形调节剂:CC趋化因子受体1和2的选择性和双靶向抑制剂